Alexandre Lambert
Impact in
Papers in
- Co-authors
- Elizabeth R. Plimack (5 shared papers)Abdel Saci (3 shared papers)Andrea Necchi (4 shared papers)Padmanee Sharma (4 shared papers)Alex Azrilevich (4 shared papers)Arlene O. Siefker‐Radtke (4 shared papers)Matthew D. Galsky (3 shared papers)Marc‐Oliver Grimm (3 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Blood (6 papers)Annals of Oncology (4 papers)JNCI Journal of the National Cancer Institute (1 paper)Pharmaceutical Statistics (1 paper)
- Partner nations
- United StatesBelgiumGermany
In The Last Decade
Alexandre Lambert
27 papers receiving 2.5k citations
Alexandre Lambert's Hit Papers
Peers
Comparison fields: 5 of 70
- Oncology 1.8k
- Genetics 300
- Immunology 579
- Hematology 255
- Surgery 1.0k
Countries citing papers authored by Alexandre Lambert
This map shows the geographic impact of Alexandre Lambert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Lambert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Lambert more than expected).
Fields of papers citing papers by Alexandre Lambert
This network shows the impact of papers produced by Alexandre Lambert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Lambert. The network helps show where Alexandre Lambert may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexandre Lambert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1203 |
| 2 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Hit paper breakdown → | 2014 | 865 |
| 3 | 2010 | 180 | |
| 4 | 2014 | 59 | |
| 5 | 2014 | 55 | |
| 6 | 2017 | 49 | |
| 7 | 2009 | 29 | |
| 8 | 2016 | 23 | |
| 9 | 2008 | 19 | |
| 10 | 2011 | 18 | |
| 11 | 2019 | 15 | |
| 12 | 2016 | 12 | |
| 13 | 2020 | 9 | |
| 14 | 2019 | 8 | |
| 15 | 2009 | 5 | |
| 16 | 2009 | 5 | |
| 17 | 2013 | 4 | |
| 18 | 2019 | 4 | |
| 19 | 2014 | 3 | |
| 20 | 2010 | 2 |
About Alexandre Lambert
Alexandre Lambert is a scholar working on Oncology, Genetics, Hematology, Surgery and Molecular Biology, having authored 27 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (9 papers), Bladder and Urothelial Cancer Treatments (8 papers), Eosinophilic Disorders and Syndromes (5 papers), CAR-T cell therapy research (3 papers), Epigenetics and DNA Methylation (3 papers) and Urinary and Genital Oncology Studies (3 papers). The work is most often cited by research in Oncology (1.8k citations), Genetics (300 citations), Immunology (579 citations), Hematology (255 citations) and Surgery (1.0k citations). Alexandre Lambert has collaborated with scholars based in United States, Belgium and Germany. Frequent co-authors include Elizabeth R. Plimack, Abdel Saci, Andrea Necchi, Padmanee Sharma, Alex Azrilevich, Arlene O. Siefker‐Radtke, Matthew D. Galsky, Marc‐Oliver Grimm, Daniel A. Vaena and Ari David Baron. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, JNCI Journal of the National Cancer Institute and Pharmaceutical Statistics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.